Azaindole derivative having PGD2 receptor antagonistic activity

Details Azaindole derivative having PGD2 receptor antagonistic activity Azaindole derivative having PGD2 receptor antagonistic activity

2006-07-20

2010-11-30

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S300000, C544S127000, C546S113000

Reexamination Certificate

active

07842692

ABSTRACT:
The present invention creates an azaindole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further providing a therapeutic agent for treating allergic diseases.A compound of the general formula (I)wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of —X1═X2—X3═X4— is a formula of —C(R1)═C(R2)—C(R3)═N— etc.; R1, R2, R3, R4and R5are independently a hydrogen atom or a halogen atom etc.; R6is optionally substituted C1-C6 alkyloxy etc.; R7is independently a halogen atom etc.; R8is optionally substituted C1-C6 alkyl etc.; R9is carboxy etc.; M is sulfonyl etc.; Y is a single bond etc.; L1, L2and L3are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.

REFERENCES:
patent: 2005/0004096 (2005-01-01), Torisu et al.
patent: 2005/0004097 (2005-01-01), Torisu et al.
patent: 2005/0096376 (2005-05-01), Sundermann et al.
patent: 2005/0171143 (2005-08-01), Tanimoto et al.
patent: 2005/0272756 (2005-12-01), Leblanc et al.
patent: 1 424 325 (2004-06-01), None
patent: 1 424 335 (2004-06-01), None
patent: 1 505 061 (2005-02-01), None
patent: 2 407 318 (2005-04-01), None
patent: 01/79169 (2001-10-01), None
patent: 02/094830 (2002-11-01), None
patent: 03/022813 (2003-03-01), None
patent: 03/022814 (2003-03-01), None
patent: 03/062200 (2003-07-01), None
patent: 03/066047 (2003-08-01), None
patent: 03/097042 (2003-11-01), None
patent: 03/097598 (2003-11-01), None
patent: 03/101961 (2003-12-01), None
patent: 03/101981 (2003-12-01), None
patent: 2004/007451 (2004-01-01), None
patent: 2004/039807 (2004-05-01), None
patent: 2004/103970 (2004-12-01), None
patent: 2004/106302 (2004-12-01), None
patent: 2004/111047 (2004-12-01), None
patent: 2005/009958 (2005-02-01), None
patent: 2005/019171 (2005-03-01), None
patent: 2005/019208 (2005-03-01), None
patent: 2005/040112 (2005-05-01), None
patent: 2005/040114 (2005-05-01), None
patent: 2005/044260 (2005-05-01), None
patent: 2005/054232 (2005-06-01), None
patent: 2005/056527 (2005-06-01), None
Robert A. Coleman et al., “VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes”, Pharmacological Reviews, vol. 46, No. 2, pp. 205-229, 1994.
International Search Report issued Sep. 5, 2006 in the International (PCT) Application PCT/JP2006/314346 of which the present application is the U.S. National Stage.

Affiliated with

Also associated with

Rating

Azaindole derivative having PGD2 receptor antagonistic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azaindole derivative having PGD2 receptor antagonistic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindole derivative having PGD2 receptor antagonistic activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4195839